stoxline Quote Chart Rank Option Currency Glossary
  
Theriva Biologics, Inc. (TOVX)
0.4844  -0.013 (-2.54%)    07-15 14:43
Open: 0.488
High: 0.5
Volume: 145,334
  
Pre. Close: 0.497
Low: 0.4672
Market Cap: 4(M)
Technical analysis
2025-07-15 2:20:48 PM
Short term     
Mid term     
Targets 6-month :  0.58 1-year :  0.64
Resists First :  0.5 Second :  0.55
Pivot price 0.45
Supports First :  0.41 Second :  0.34
MAs MA(5) :  0.48 MA(20) :  0.45
MA(100) :  0.91 MA(250) :  1.9
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  82.8 D(3) :  85.1
RSI RSI(14): 48.1
52-week High :  7.25 Low :  0.4
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ TOVX ] has closed below upper band by 18.6%. Bollinger Bands are 77.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.51 - 0.51 0.51 - 0.52
Low: 0.47 - 0.48 0.48 - 0.48
Close: 0.49 - 0.5 0.5 - 0.5
Company Description

Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.

Headline News

Wed, 25 Jun 2025
Theriva Biologics Sets 2025 Shareholder Meeting Date - TipRanks

Fri, 20 Jun 2025
Theriva Biologics Announces At-The-Market Stock Offering - TipRanks

Tue, 27 May 2025
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer - Yahoo Finance

Wed, 14 May 2025
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results - Yahoo Finance

Thu, 08 May 2025
Theriva Biologics Announces Closing of $7.5 Million Public Offering - Stock Titan

Wed, 07 May 2025
Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 1.2 (%)
Held by Institutions 5.3 (%)
Shares Short 245 (K)
Shares Short P.Month 2 (K)
Stock Financials
EPS -31.25
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 28.92
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -25 %
Return on Equity (ttm) -59.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -21.19
Qtrly Earnings Growth 0 %
Operating Cash Flow -18 (M)
Levered Free Cash Flow -15 (M)
Stock Valuations
PE Ratio -0.02
PEG Ratio 0
Price to Book value 0.01
Price to Sales 0
Price to Cash Flow -0.03
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android